Xeris Biopharma Holdings (XERS) Share-based Compensation (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Share-based Compensation of $17.0 million for Q1 2026, up 373.67% on a QoQ basis from -$6.2 million in Q4 2025, and up 112.77% year-over-year from $8.0 million in Q1 2025.
Xeris Biopharma Holdings (XERS) Share-based Compensation (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Share-based Compensation history runs 7 years deep, the most recent figure standing at $17.0 million for Q1 2026.
- Quarterly Share-based Compensation rose 112.77% year-over-year to $17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (up 149.78% YoY) and the FY2025 annual result came in at $10.9 million, up 191.27% from the prior year.
- Share-based Compensation was $17.0 million for Q1 2026 at Xeris Biopharma Holdings, up from -$6.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $20.0 million in Q2 2023 and bottomed at -$6.2 million in Q4 2025.
- A 5-year average of $5.0 million and a median of $2.9 million in 2022 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 9108.43% in 2025, while the deepest fall reached 3845.78% in 2025.
- Xeris Biopharma Holdings' Share-based Compensation stood at $12.2 million in 2022, then slumped by 99.6% to $49000.0 in 2023, then soared by 238.78% to $166000.0 in 2024, then tumbled by 3845.78% to -$6.2 million in 2025, then jumped by 373.67% to $17.0 million in 2026.
- Business Quant data shows XERS's Share-based Compensation at $17.0 million in Q1 2026, -$6.2 million in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 17.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.02 Mn |
| Mar 31, 2026 | 17.02 Mn |
| Dec 31, 2025 | -6.22 Mn |
| Dec 31, 2025 | -6.22 Mn |
| Sep 30, 2025 | 7.64 Mn |
| Sep 30, 2025 | 7.64 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Dec 31, 2024 | 166,000.00 |
| Dec 31, 2024 | 166,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | -282,000.00 |
| Jun 30, 2024 | -282,000.00 |
| Mar 31, 2024 | 3.77 Mn |
| Mar 31, 2024 | 3.77 Mn |
| Dec 31, 2023 | 49,000.00 |
| Dec 31, 2023 | 49,000.00 |